Twenty-nine hospital trusts listed by NHS England as benefiting from Palantir’s federated data platform said the system was not live or they were not using its applications, according to a Guardian report published November 2. The responses raise questions about how the agency describes uptake of the £330 million platform.
The findings came from more than 100 freedom of information requests obtained by Medact, a medical charity campaigning to remove Palantir from the NHS, and shared with the newspaper. The platform is intended to connect medical information and improve tasks including discharge planning and surgery scheduling.
Among the responses, Nottingham University Hospitals said it had not agreed an implementation timetable. University Hospitals of North Midlands said the platform was not live and it had no plans to introduce it.
NHS England defended its figures, saying nearly 140 trusts had reported benefits from the platform’s tools. Its definition includes administrative data analysis and submissions, not just applications supporting patient care. Torbay and South Devon, for example, was counted as live because data-submission infrastructure was installed, despite reporting no operational use of the platform.
The Office for Statistics Regulation said it would examine the benefit claims through its casework process. NHS England had previously acknowledged that it could not establish that the platform caused the additional operations it reported at participating trusts.
Chi Onwurah, chair of the Commons science and technology committee, urged ministers to use a 2027 contract break clause and seek a UK-owned supplier. Palantir defended its software, citing improvements in operations, discharge delays and cancer diagnosis timeliness. Those figures do not resolve the dispute over how participating trusts are classified.
Reader comments (0)
Bring evidence, ask questions, or challenge our reporting. Every comment is checked before publication.
No approved comments yet
Be the first to ask a thoughtful question or contribute useful context. We won't invent reader conversations.
Join the discussion
Members-only commenting
Everyone can read comments. To write, verify your email and sign in to your free member account.
Sign in or join freeNo newsletter subscription is required. Your email address remains private.